Trialscope

Biopharma teams monitor public trial registries, regulatory calendars, labels, safety notices and company disclosures for competitor changes. The supplied research confirms a unified life-sciences data interface, a free public trial registry interface and an enterprise competitive-intelligence market. It finds no lightweight team-channel trial-diff service in the proposed range; that is a researched gap, not proof of no competitor. Trialscope reports only observable public-source changes. A primary endpoint edit, arm addition, recruitment status change, result posting, advisory-calendar entry and sponsor announcement are different events. Registry fields are generally sponsor- or investigator-submitted, can lag reality and can be corrected. A field diff never proves the reason, clinical significance, safety finding, data-monitoring decision or regulatory position. Private meetings and nonpublic committee actions cannot be inferred. A security-price movement is excluded as a trial-causality signal; market movement has many causes and would require separate licensed data and analysis. Every alert preserves source, record, field, prior and new value, record date, retrieval time, source version, coverage and uncertainty. Automated relevance is a routing aid, not medical, regulatory or investment advice. Alert delivery, recipient acknowledgment, analyst disposition, internal memo and later company or market outcome remain separate.

A small or mid-sized biotech competitive-intelligence, clinical strategy or business-development team monitoring a defined therapeutic-area watchlist.